



for serodiagnosis of human

fascioliasis by Sudirman, Nur Hafizah
DEVELOPMENT OF AN IN-HOUSE ENZYME-
LINKED IMMUNOSORBENT ASSAY (ELISA) 




























DEVELOPMENT OF AN IN-HOUSE ENZYME-
LINKED IMMUNOSORBENT ASSAY (ELISA) 














Dissertation submitted in partial fulfilment of 
the requirements of the degree of 








All praise and gratitude to the Almighty in His Grace for bestowing upon me the 
opportunity to be a part of this program and easing my journey throughout the course . 
 
I am deeply indebted to my supervisor, Dr. Wan Nor Amilah Wan Abdul 
Wahab, and my co-supervisor, Dr. Noor Izani Noor Jamal, for their limitless patience, 
kindness and encouragement in guiding me throughout the completion of dissertation 
despite my personal struggles. I am also exceedingly grateful to our course 
coordinator, Dr. Wong Weng Kin, for his many advice and tireless commitment, and 
to the rest of administration staff for their effort and hard work, in ensuring the program 
could continue smoothly in the midst of the COVID-19 movement control order. 
 
I have also been extremely fortunate to receive invaluable assistance and 
advice from my postgraduate senior, Mr Ahmad Najib Mohamad, in response to my 
queries in dissertation writing and other technical aspects. 
 
My sincerest appreciation to my fellow postgraduate students and friends as 
well for their support, motivation and encouragement throughout the course. Finally, 
I would like to dedicate this dissertation to my dear mother, for her unconditional 
support, strength and patience as I embarked on this journey until its completion, and 
I hope she would be proud of this work.   
 
iii 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ....................................................................................... ii 
TABLE OF CONTENTS .......................................................................................... iii 
LIST OF TABLES .................................................................................................... vi 
LIST OF FIGURES ................................................................................................. vii 
LIST OF SYMBOLS ................................................................................................ ix 
LIST OF ABBREVIATIONS ................................................................................... x 
ABSTRAK ................................................................................................................ xii 
ABSTRACT ............................................................................................................. xiv 
CHAPTER 1 INTRODUCTION .......................................................................... 1 
1.1 Study Background ............................................................................................ 1 
1.2 Problem Statement ........................................................................................... 2 
1.3 Rationale of Study ............................................................................................ 4 
1.4 Research Question ............................................................................................ 5 
1.5 Study Objectives .............................................................................................. 5 
1.5.1 General Objective ............................................................................ 5 
1.5.2 Specific Objectives .......................................................................... 6 
1.6 Flowchart of Study ........................................................................................... 7 
CHAPTER 2 LITERATURE REVIEW .............................................................. 8 
2.1 Introduction ...................................................................................................... 8 
2.2 Life Cycle and Transmission of Fasciola spp. ............................................... 10 
2.3 Morphology of Adult Flukes of Fasciola spp. ............................................... 12 
2.4 Epidemiology ................................................................................................. 16 
2.5 Pathogenesis and Clinical Manifestations ...................................................... 19 
2.6 Clinical Approach to Diagnosis and Treatment ............................................. 21 
2.7 Laboratory Diagnostic Approaches ................................................................ 22 
iv 
2.7.1 Parasitological Diagnosis ............................................................... 23 
2.7.2 Immunodiagnosis ........................................................................... 24 
2.7.3 Molecular Diagnosis ...................................................................... 33 
CHAPTER 3 METHODOLOGY....................................................................... 34 
3.1 Materials ......................................................................................................... 34 
3.1.1 Fasciola gigantica Adult Flukes .................................................... 34 
3.1.2 Human Serum Samples .................................................................. 34 
3.1.3 List of Chemicals ........................................................................... 38 
3.1.4 List of Kits and Consumables ........................................................ 38 
3.1.5 List of Equipment ........................................................................... 38 
3.2 Preparation of Crude Soluble Antigen (CSA) of F. gigantica ....................... 41 
3.3 Determination of Protein Concentration by Bradford Assay ......................... 41 
3.4 Determination of F. gigantica CSA Quality by SDS-PAGE ......................... 44 
3.5 Development of F. gigantica CSA-IgG-ELISA ............................................ 44 
3.5.1 Optimization of Coating CSA Concentration ................................ 45 
3.5.2 Optimization of Human Serum Sample Dilution ........................... 46 
3.5.3 Optimization of HRP-conjugated Antibody Dilution .................... 46 
3.5.4 Determination of In-house ELISA Cut-off Value .......................... 47 
3.6 Statistical Analysis ......................................................................................... 47 
CHAPTER 4 EXPECTED RESULTS ............................................................... 49 
4.1 Fasciola gigantica Crude Soluble Antigen (CSA) ........................................ 49 
4.2 CSA Protein Concentration ............................................................................ 49 
4.3 Optimization of Parameters for the in-house CSA-IgG-ELISA .................... 52 
4.3.1 Optimization of Coating CSA Concentration ................................ 52 
4.3.2 Optimization of Serum Sample Dilution ....................................... 52 
4.3.3 Optimization of Horseradish Peroxidase-conjugated (HRP) 
Antibody Dilution .......................................................................... 55 
v 
4.4 Screening of Selected Cattle-breeder Serum Samples using The 
Optimized In-house ELISA ............................................................................ 57 
4.5 Receiver-Operator Characteristic (ROC) Analysis of In-house ELISA ........ 60 
CHAPTER 5 DISCUSSION ............................................................................... 63 
CHAPTER 6 CONCLUSION AND FUTURE RECOMMENDATIONS ...... 69 
6.1 Conclusion ...................................................................................................... 69 
6.2 Study Limitations and Future Recommendations .......................................... 69 




LIST OF TABLES 
Page 
Table 2.1 Epidemiological classification of human fascioliasis prevalence 
and infection intensities. .................................................................... 17 
Table 2.2 Summary of antigens used and evaluated in antibody-detection 
ELISAs for human fascioliasis in selected past studies. .................... 29 
Table 2.3 Commercially available antibody-detection ELISA test kits for 
diagnosis of fascioliasis in humans. ................................................... 32 
Table 3.1 List of chemicals used in this study ................................................... 39 
Table 3.2 List of kits and consumables used in this study ................................. 40 
Table 3.3 List of equipment used in this study .................................................. 40 
Table 3.4 Description of parameters included in the evaluation of diagnostic 
performance of CSA-IgG-ELISA. ..................................................... 48 
Table 4.1 Values of optimized variables for CSA-IgG-ELISA ......................... 58 
Table 4.2 Comparison of  the number of serum samples with positive and 
negative readings between in-house ELISA and commercial 
ELISA kit ........................................................................................... 59 
Table 4.3 Expected  diagnostic performance of in-house F. gigantica CSA-
IgG-ELISA. ........................................................................................ 62 
 
vii 
LIST OF FIGURES 
Page 
Figure 1.1 The flowchart of study ......................................................................... 7 
Figure 2.1 Taxonomy of Fasciola spp................................................................... 9 
Figure 2.2 The two-host life cycle of Fasciola spp. in intermediate hosts 
(i.e.snail) and definitive host (i.e. ruminants and humans). ............... 13 
Figure 2.3 (a) Morphology of adult fluke of F.hepatica isolated from sheep. 
(b) Morphology of adult fluke of F. gigantica isolated from cattle. 
(c) Structures of an adult F. hepatica fluke........................................ 14 
Figure 2.4 Standardized measurements obtained under microscope of gravid 
F. hepatica adult fluke (left) and F. gigantica adult fluke (right). ..... 15 
Figure 2.5 Worldwide distribution of Fasciola spp. infection, based on data 
of the most recent year available. ....................................................... 18 
Figure 3.1 Adult fluke of F. gigantica isolated from the liver of a cattle. .......... 35 
Figure 3.2 OD (optical density) readings obtained from commercial ELISA 
in the previous phase of study. ........................................................... 37 
Figure 3.3 Whole adult fluke of F. gigantica was grounded to fine powder ...... 43 
Figure 3.4 Six protein standards and one blank sample (far left) prepared in 
Bradford protein assay for CSA protein determination ..................... 43 
Figure 4.1 Protein profile of F. gigantica CSA by SDS-PAGE .......................... 50 
Figure 4.2 Bovine serum albumin (BSA) standards curve of Bradford protein 
assay. .................................................................................................. 51 
Figure 4.3 Optimization of CSA coating concentration ...................................... 53 
Figure 4.4 Optimization of serum dilution against CSA ..................................... 54 
Figure 4.5 Optimization of HRP-conjugated secondary antihuman IgG 
dilution against human sera ................................................................ 56 
viii 
Figure 4.6 ROC curve of optimized CSA-IgG-ELISA using pooled positive 
and negative samples from cattle breeders in Kelantan obtained 






LIST OF SYMBOLS 
% Percentage 
< Lower than 
> Greater than 













LIST OF ABBREVIATIONS 
AUC Area Under Curve 
BSA Bovine Serum Albumin 
CDC Centers for Disease Control and Prevention 
CI Confidence Interval 
CIAS Computer Image Analysis System 
CL1 Cathepsin L1 
CSA Crude Soluble Antigen 
CT Computer Topography scan 
ELISA Enzyme-Linked Immunosorbent Assay 
epg Eggs per Gram 
ES Excretory/Secretory 
et al  And Others 
HRP Horseradish Peroxidase 
i.e. Id est (That is) 
IgA Immunoglobulin A 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
Inc. Incorporation 
INFORMM Institute for Research in Molecular Medicine 
JEPeM Jawatankuasa Etika Penyelidikan Manusia 
kDa Kilo Dalton 
MRI Magnetic Resonance Imaging 
NaCl Sodium Chloride 
NPA Negative Percent Agreement 
NPV Negative Predictive Value 
NTD Neglected Tropical Disease 
OD Optical Density 
p.i. Post-infection 
PBS Phosphate Buffer Solution 
PCR Polymerase Chain Reaction 
PPA Positive Percent Agreement 
xi 
PPV Positive Predictive Value 
ROC Receiver Operating Characteristic 
SDS-PAGE Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
SGD Sustainable Development Goals 
spp. Species (plural form) 
SPSS Statistical Package for Social Sciences 
USA United States of America 
USM Universiti Sains Malaysia 




PEMBANGUNAN ELISA DALAMAN BAGI SERODIAGNOSIS 
FASIOLIASIS MANUSIA 
ABSTRAK 
Fasioliasis ialah sejenis jangkitan parasit tularan air dan makanan oleh Fasciola spp. 
yang menjangkiti haiwan dan manusia. Kaedah diagnostik standard bagi jangkitan 
fasioliasis manusia adalah bergantung pada pengesanan telur fasciolid secara 
koprologi yang kurang sensitf dan hanya sesuai untuk diagnosis jangkitan kronik. 
Kaedah serodiagnosis boleh digunakan untuk menambah baik kapasiti diagnosis 
fasioliasis bagi tujuan klinikal dan penyelidikan. Tujuan kajian ini adalah untuk 
membangunkan dan mengoptimum ELISA dalaman tidak langsung berdasarkan 
antigen kasar F. gigantica untuk tujuan serodiagnosis dalam kalangan penduduk 
tempatan. Dalam kajian ini, antigen larut kasar (CSA) disediakan daripada cacing 
dewasa dan diguna dalam pengoptimunan ELISA dalaman. Sembilan puluh sampel 
arkib serum manusia yang diperoleh dari kajian keratan rentas terdahulu (60 
seropositif, 30 seronegatif) disaring menggunakan ELISA yang dibangunkan. Nilai 
pemotong esai ini ditentukan dengan plot analisis lengkung ciri operasi penerima 
(ROC) dan peratusan persetujuan ini dibandingkan dengan kit ELISA komersial 
(Diagnostics Automation/Cortez Diagnostics, USA). Kepekatan salutan antigen, 
pencairan serum manusia dan pencairan antibody sekundar dikonjugasi HRP 
dioptimumkan masing-masing pada 20 µg/mL, 1:100 dan 1:6000. Esai ini 
menunjukkan prestasi yang hampir setara dengan kit ELISA komersial pada nilai 
pemotongan 0.65 (nilai kappa=0.910), dengan peratusan persetujuan positif dan 
peratusan persetujuan negatif masing-masing pada 100% dan 96.67%.. 
Kesimpulannya, ELISA dalaman yang dibangunkan adalah setanding dengan ELISA 
xiii 
komersial dalam kajian ini dan berpotensi untuk diaplikasikan dalam serodiagnosis 
fasioliasis manusia dalam komuniti.  
  
xiv 
DEVELOPMENT OF AN IN-HOUSE ENZYME-LINKED 
IMMUNOSORBENT ASSAY (ELISA) FOR SERODIAGNOSIS OF HUMAN 
FASCIOLIASIS 
ABSTRACT 
Fascioliasis is waterborne and foodborne parasitic disease caused by Fasciola spp. 
which infect animals and humans. Current gold standard of human diagnosis relies on 
coprological detection of fasciolid eggs which lacks sensitivity and only applicable in 
chronic infections. Serodiagnosis can be used to improve diagnostic capacity of 
fascioliasis for both clinical and research purposes. The aim of this study was to 
develop and optimize an in-house indirect ELISA based on F. gigantica crude antigen 
for serodiagnosis of human fascioliasis in local population. In the study, a crude 
soluble antigen (CSA) was prepared from adult flukes and was used in the optimization 
of in-house ELISA. Ninety archived human sera from a previous cross-sectional study 
(60 seropositive, 30 seronegative) were screened using the developed ELISA. The cut-
off value of the assay was determined by plotting the receiver-operating characteristic 
(ROC) curve analysis and the percentage agreements were calculated in comparison 
to a commercially available ELISA kit (Diagnostics Automation/Cortez Diagnostics, 
USA). The coating antigen concentration, serum dilution and HRP-conjugated 
secondary antibody dilution were optimized at 20 µg/mL, 1:100, and 1:6000 
respectively. The assay exhibited near perfect agreements with the commercial ELISA 
kit at a cut-off value of 0.65 (kappa value=0.910) in which the positive percent 
agreement and negative percent agreement were 100% and 96.7 % respectively. In 
conclusion, the developed in-house ELISA is comparable to that of commercial ELISA 
xv 
in this study and is potentially applicable for the serodiagnosis of human fascioliasis 







CHAPTER 1  
 
INTRODUCTION 
1.1 Study Background 
Fascioliasis is a human and animal parasitic disease caused by Fasciola spp. The main 
infective species are Fasciola hepatica (which has a wider and more cosmopolitan 
distribution across Europe and Americas) and Fasciola gigantica, (more common for 
countries in Africa and Asia, including Malaysia). The foodborne trematodiasis is 
recognized by World Health Organization (WHO) as one of the important global 
neglected tropical disease (NTD) due to the morbidity as well as economic losses 
caused by the decrease in milk and meat production, particularly in rural and farming 
communities (Mas-Coma, 2004). 
Human fascioliasis was initially seen as a disease secondary to its animal 
counterpart, with reported sporadic cases amounted to only 2,000 between 1970s until 
1990s. The situation changed when WHO launched a worldwide investigation which 
led to its recognition as an emerging or re-emerging tropical disease and requires 
global attention (Mas-Coma, 2009). Human fascioliasis is estimated to affect 2.4 
million to 17 million people worldwide, with the highest incidence in Peru’s and 
Northern Bolivian Altiplano, while the number of people at risk of infection is 
estimated at 180 million (Mas-Coma, 2005; Figueroa et al, 2006). The global human 
fascioliasis distribution stretches extensively across regions in Americas, Europe, 
Africa and Asia. Vietnam, Thailand and Philippines are known as the major endemic 
countries of this disease in Southeast Asia (Mas-Coma et al, 2005a). Malaysia has only 
one human case of fascioliasis reported, and no prevalence analysis has been 
documented thus far (Naresh et al, 2006; Najib et al, 2020b). 
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The major source of infection for both ruminants and human is the 
consumption of aquatic vegetables such as lettuce and water cress; and edible plants 
that are washed with water contaminated with the cystic stage metacercaria (Walker 
et al., 2008). Studies carried out in Ethopia found signficant risk association with sheep 
and/or cattle ownership, besides raw vegetable consumption, use of unsafe drinking 
water sources, and irrigation practices (Fentie et al., 2013). Diagnosis of fascioliasis is 
accomplished by the identification of eggs in the coprological microscopic 
examination, which is considered as a “gold standard”, or by the immunological testing 
of serum and/or stool samples (Mas-Coma et al, 2014; Sarkari et al, 2017). 
Chemotherapy with triclabendazole is the mainstay of fascioliasis treatment, although 
resistance to this drug has been reported (Cabada et al, 2006; Diaz et al, 2010).  
1.2 Problem Statement 
The epidemiological status of human fascioliasis has been well-documented across the 
globe, particularly in the endemic regions that have suffered significant morbidity such 
as Peru, Iran, Egypt and Vietnam. Numerous prevalence studies on ruminant 
fascioliasis have been carried out in Malaysia, many of which focus on cattle (Khadijah 
et al, 2019; Masrin et al, 2015; Rita et al, 2017; Zainalabidin et al, 2015). A study 
conducted by Diyana et al revealed the highest prevalence of bovine fascioliasis in the 
Bukit Tengah Regional Veterinary Laboratory (5.55%), (Diyana et al, 2019). 
Terengganu is the most endemic state for ruminant fascioliasis, with 82% 
seroprevalence in cattle, and 89% seroprevalence in sheep and goat (Khadijah et al, 
2017; Rita et al, 2017). To date, data regarding the seroprevalence and distribution of 
human fascioliasis in Malaysia is fragmented or not well documented. The previous 
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study has demonstrated 37.3% and 67% seroprevalence of fascioliasis among farmed 
cattle and cattle breeders in Kelantan respectively (Najib, 2020a). 
Currently, fascioliasis is diagnosed based on egg or F. hepatica-specific 
antigen detection in faeces or by antibody detection in serum or milk. All these assays 
have some limitations; for example, egg shedding by adult flukes only occurs 3 – 4 
months post-infection (p.i.); hence, coprological examination is only feasible in 
chronic infections, during which severe liver damage and other complications may 
have already occur (Chen and Mott, 1990; Mas-Coma et al 2014; Sarkari et al, 2017). 
The eggs may also still be undetectable in this period due to low infection burden, 
irregular egg-shedding, or the intermittent nature of egg production. Thus necessitating 
repeated examinations over several days which is time-consuming (Mas-Coma et al, 
2014). Delay in obtaining results often leads to delay in the commencement of 
treatment in the absence of definitive diagnosis. Availability of an effective, simple 
and cost-effective diagnostic tool will enable infected individuals to be treated in a 
targeted manner, and will help the community to move away from the traditional 
repeated blanket treatment regime. Human immune response to Fasciola antigens 
occurs early in infection. Antibody detection using an immunological method such as 
enzyme-linked immunosorbent assay (ELISA) may be regarded as a more reliable, 
easier and cheaper mean in evaluating the prevalence rate and disease exposure of 
human fascioliasis than coprological analysis especially among high risk individuals 
such as farm workers and animal breeders. An in-house ELISA for human fascioliasis 
is not yet available and such testing would be equally as reliable and accurate, as well 
as more cost effective if used for local screening or diagnostic evaluation in the 
community.  
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1.3 Rationale of Study 
ELISA is a serodiagnostic tool routinely used for immunodiagnosis in acute infection 
and its excellent specificity and sensitivity have been proven in multiple past studies 
(O’Neill et al, 1999; Espenoza et al, 2007; Valero et al, 2012a Khan et al, 2017;). 
Indirect ELISA is the most frequently used test in serodiagnosis of human fascioliasis 
because of the relative simplicity and early detection of infection (usually 1–2 weeks) 
(Sanchez-Andrade et al, 2001). Its high level of specificity has been proven in studies 
conducted in developed countries (Mas-Coma et al, 2014; Sarkari and Khabisi, 2017). 
It is also capable of diagnosing asymptomatic or subclinical fascioliasis and ectopic 
fascioliasis where no eggs are shed in stool for detection by coprological examination 
(Mas-Coma et al, 2014). The aforementioned advantages as well as its ease of 
application and relatively rapid result makes it a preferred diagnostic tool for use in 
human fascioliasis seroprevalence studies in Malaysia, of which the present data is 
unavailable. 
Currently, the commercial ELISA kit available for use in our country is 
Fasciola IgG ELISA manufactured by Diagnostic Automation/Cortez Diagnostics, 
Inc. (USA). Conducting a surveillance study involving a large sample size using 
imported kit would incur high cost to the research. Moreover, the commercial kit is 
constructed based on F. hepatica antigen and could potentially produce less accurate 
result for diagnosis of human fascioliasis in Malaysia, which is endemic for F. 
gigantica species. Furthermore, the result interpretation may be misleading when 
tested in the local population as the cut-off values of anti-Fasciola titre are different 
compared to the manufacturer's value at different geographical areas. Developing an 
in-house ELISA test that corresponds to the local settings would be extremely valuable 
in terms of study cost-effectiveness as well as ensuring improved accuracy in 
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serodiagnosis of fascioliasis. Serodiagnosis remains an important approach in routine 
diagnosis (in addition to thorough clinical assessment of the infected patient) due to 
its many advantages over the conventional method. In the long run, determining and 
establishing the current seroprevalence and epidemiology of human fascioliasis in 
Malaysia will certainly be useful in designing appropriate control measures and 
prevention strategies to improve the economic status of endemic areas, such as those 
of farming and cattle breeding communities in Perak, Terengganu and Kelantan. 
Therefore, this research aims to develop an in-house ELISA serodiagnostic test 
and to compare its performance with a currently available commercial fascioliasis 
serodiagnosis kit for human fascioliasis. The research findings are essential to the 
health service providers in the state to assist cattle breeders in monitoring and/or 
controlling of the zoonotic disease to reduce the risk of ecomonic loss and improve the 
economic wellbeing and health of the cattle breeders. 
1.4 Research Question 
Is anti-Fasciola IgG antibody detection by the developed in-house ELISA in good 
agreement with that of commercial ELISA kit? 
1.5 Study Objectives 
1.5.1 General Objective 
The general objective of this study was to develop an in-house ELISA for 
serodiagnosis of human fascioliasis and evaluate its diagnostic performance. 
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1.5.2 Specific Objectives 
1) To develop and optimize an in-house ELISA for detection of anti-Fasciola IgG 
antibodies in human sera. 
2) To compare the positive and negative percentage agreements between the in-
house ELISA and the commercial ELISA kit. 
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1.6 Flowchart of Study  



























Figure 1.1 The flowchart of study 
 
Preparation of crude soluble 
antigen (CSA) 
Protein concentration determination 
 
Development and evaluation of customized indirect ELISA (Optimization): 
- General ELISA procedure 
- Optimization of coating crude antigen  
- Optimization of serum dilution 
- Determination of ELISA cut-off value 
Sample screening 
Determine percentage of agreement 
Statistical analysis 
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Fascioliasis is a waterborne and foodborne zoonotic disease caused by two parasites of 
genus Fasciola. According to animal taxonomy, Fasciola spp. belong to class 
Trematoda under phylum Platyhelminthes within the kingdom Animalia. Beneath the 
class Trematoda, it is classified under order Protostome, suborder Echinostomata, 
superfamily Fasciolidiae, and genus Fasciola (Figure 2.1). The main Fasciola species 
commonly related to the human parasitic disease are Fasciolia hepatica and Fasciola 
gigantica (Keiser and Utzinger, 2009). 
F. hepatica is commonly found in countries with temperate weather such as 
Europe, the Americas, the Oceania, and some parts of Africa and Asia. Meanwhile, F. 
gigantica has a more restricted global distribution which is mainly located in tropical 
regions of Africa and Asia (Valero et al, 2009). Both species have been found to co-
exist or overlap in Egypt, Asia Japan, Korea and Philippines (Mas-Coma, 2005a; Valero 
et al, 2009). The most recent esteimated number of human fascioliasis cases is around 
17 million globally with F. hepatica being the dominant infective strain due to its higher 




Figure 2.1 Taxonomy of Fasciola spp. (Keiser and Utzinger, 2009) 
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Human fascioliasis was regarded as a secondary disease that had resulted from 
its ruminant counterpart in areas endemic of the animal disease. However, as the trend 
in the number of human cases continued to increase even in areas with sporadic animal 
fascioliasis in the 1980s and 1990s, human infection was beginning to be treated with 
its own importance (Ashrafi et al., 2014), so much so that WHO has included human 
fascioliasis as one of the neglected tropical infections which required control and 
prevention measure on a global level (Valero et al., 2009; WHO, 2017). This 
importance is further strengthened by the evidence of its impact on the economic losses 
in livestock as well as meat and dairy production which is vital to the livelihood of many 
rural farming communities in developing countries (Mas-Coma et al., 2005b; Mehmood 
et al., 2017). 
In line with Sustainable Development Goals (SGD), WHO had implemented a 
series of global measures dubbed as “The NTD Roadmap to 2020” in a bid to reduce 
the worldwide prevalence and burden of tropical diseases, of which human fascioliasis 
is included, by means of elimination and eradication particularly in poor and developing 
countries beginning in 2013 with a set of goals to achieve by 2020. The WHO Strategic 
and Technical Advisory Group for Neglected Tropical Diseases has addressed the 
challenges of the roadmap and proposed its extension and further development for the 
next decade (WHO, 2020).  
2.2 Life Cycle and Transmission of Fasciola spp. 
Fascioliasis is a zoonotic disease that infects both animals and humans, also referred to 
as the definitive or reservoir hosts. The animals that host this parasite are common 
livestock ruminants such as cattle, sheep, buffaloes and goats, and wild animals such as 
deer, rodents, horses, wild pigs, mules and camels (Ashrafi et al., 2014; Mas-Coma, 
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2004; Sripa et al, 2010). Fasciolids’ two-host lifecycle occurs in four main phases and 
takes place in approximately 14 to 23 weeks (Figure 2.2) (Mas-Coma, 2004);  
(i) Definitive hosts are infected through ingestion of vegetation contaminated 
with metacercariae of the parasites. The parasitic cysts then excyst within 
the duodenum of these hosts, penetrate the intestinal walls and migrate 
through the liver to mature in the biliary tree into adult flukes. The sexual 
maturation and oviposition of flukes in humans occur around three to four 
months, while their lifespan lasts between 9 to 13.5 years 
(ii) The unembryonated eggs are expelled with the faeces into the external 
environment, become embryonated in freshwater within two weeks, and 
hatch to release miracidia under certain physicochemical properties, 
particularly that of water temperature ranging between 15 – 25 oC (Mas-
Coma, 2004). The transit between definitive mammal host and intermediate 
snail vector consists of the long resistance phase of the egg and the short 
active phase of miracidium. 
(iii) The miracidia penetrate into the snail vector and develop into sporocysts, 
rediae and cercariae. The cercariae are then shed into the water with 
temperature 9 – 26 °C regardless in daylight or night time. The duration of 
prepatent period (i.e. period between ingestion and appearance of eggs) is 
38 – 86 days, depending on temperature as higher temperatures will reduce 
the period. 
(iv) Transit between intermediate snail host and definitive mammal host includes 
the short swimming phase of cercaria and the long resistance phase of 
metacercaria. The released cercariae swim until they encounter solid 
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support, such as the leaves of nearby aquatic vegetation, and encyst to form 
metacercariae above or below the waterline. The metacercariae will become 
infective within 24 hours 
2.3 Morphology of Adult Flukes of Fasciola spp. 
The classical method of discriminating F. hepatica and F. gigantica is by observing and 
comparing the morphological characteristics of both species under microscope. 
However, the extensive phenotypic variation between the two species as well as the 
identification of hybrid or intermediate forms of Fasciola spp. in some regions has made 
this task difficult (Mas-Coma et al, 2005b). Generally, the adult worms of F. hepatica 
are shorter in length, broader and conical, whereas adult worms of F. gigantica are 
narrower, larger in size and more elongated (Figure 2.3)  In the past two decades, precise 
measurements of linear lengths, areas and ratios of the adult flukes are achieved by 
computer image analysis system (CIAS), such as shown in Figure 2.4 (i.e. BL = Body 
length, BW = maximum body width, BWOv = body width at ovary level, CL = cone 
length, CW = cone width, OS max = maximum diameter of oral sucker, OS min = 
minimum diameter of oral sucker, VS max = maximum diameter of ventral sucker, VS 
min = minimum diameter of ventral sucker, PhL = pharynx length, PhW = pharynx 
width, TL = testicular space length, TW = testicular space width; Periago et al, 2006). 
A recent comparative morphometrical analysis was carried out by Shafiei et al (2014) 
between adult flukes of F. hepatica and F. gigantica isolated from common livestock 
ruminants in southwest Iran. The study demonstrated morphometric measurements 
differences between the two species, bandut also between F. hepatica flukes isolated 




Figure 2.2 The two-host life cycle of Fasciola spp. in intermediate hosts (i.e.snail) 






Figure 2.3 (a) Morphology of adult fluke of F.hepatica isolated from sheep. (b) 
Morphology of adult fluke of F. gigantica isolated from cattle. (Shafiei et al, 2014) (c) 




Figure 2.4 Standardized measurements obtained under microscope of gravid F. 





The epidemiological classification for human fascioliasis proposed by Mas-Coma et al 
in 1999 is still useful in describing the prevalence and disease intensity in different 
regions around the world (Mas-Coma et al, 1999; Mas-Coma et al, 2018). The 
classification includes; (i) imported cases, (ii) autochthonous, isolated cases, (iii) 
epidemic situation, and (iv) endemic situations which are further classified into 
hypoendemic, mesoendemic and hyperendemic scenarios, as described in Table 2.1. To 
date, the most well-known hyperendemic region recorded for human fascioliasis lies in 
the Northern Bolivian Altiplano with prevalence of 72% and 100% for coprological and 
serological surveys respectively, with infection intensity reaching up to 5000 eggs per 
gram (epg) (Mas-Coma, 2005a). 
Interestingly, fascioliasis is recognized as the food-borne parasitic disease with 
broadest distribution (Figure 2.3) because its human endemic regions are discovered in 
areas ranging below sea-level along the Caspian, to the communities living in 
mountainous ranges (Mas-Coma et al, 2005b). F. gigantica is the sole species of 
fasciolid found in Malaysia (Khadijah et al, 2019; Rajamanickam et al, 1996). The most 
recent global estimation of human fascioliasis is 2.4 million to 17 million cases (Mas-
Coma et al, 2018). The number of cases affected by the liver fluke in the whole of Asia, 
or even in Southeast Asia alone, is yet undetermined. However, its incidence is notably 
increasing in Vietnam, which the most endemic country in this region. According to an 
official report by WHO in 2008, there has been an estimated 5000 cases throughout 
Vietnam, with more cases being reported from 2004 onwards in response to treatment 
availability. Climate change is also credited as one of the important attributes to the 
increasing incidence of human fascioliasis cases (Mas-Coma et al., 2009; Sripa et al., 
2010; WHO, 2008)  
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Table 2.1 Epidemiological classification of human fascioliasis prevalence and 
infection intensities. 
Classification Description 
Imported cases Diagnosed in a zone lacking F. hepatica (even among animals) but 
were infected in an area where F. hepatica transmission occurs 
Autochthonous cases Acquired the infection in the area where they reside and animal 
fascioliasis is also present; these cases appear non-constant and 
sporadical 
Endemic cases Hypoendemic 
<1% prevalence, mean intensity <50 eggs per gram (epg) 
Mesoendemic 
1 – 10% prevalence, mean intensity 50 – 300 epg 
 Hyperendemic 
>10% prevalence, mean intensity >300 epg 
Epidemic cases Outbreaks appearing in animal-endemic zones where previous 
human reports have always been isolated and sporadic; or 
Outbreaks in zones human-endemic in humans but involving a 
greater number of individuals than usual 




Figure 2.5 Worldwide distribution of Fasciola spp. infection, based on data of the 
most recent year available. (Gandhi et al, 2019.) 
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In Malaysia, the epidemiological studies of fascioliasis have focused mainly on 
animal disease, and published data are only limited to the states of Terengganu and 
Perak (Khadijah et al., 2017, 2019; Rita et al., 2017; Zainalabidin et al., 2015). To date, 
there has only been one published case of human fascioliasis in Malaysia in 2005 
(Naresh et al, 2006). Startlingly, a recent study conducted in cattle farms throughout 
Kelantan has demonstrated 67% seropositive prevalence among the cattle breeders 
(Najib et al, 2020c). 
2.5 Pathogenesis and Clinical Manifestations 
Fascioliasis is a zoonotic disease typically transmitted from livestock to humans 
through ingestion of aquatic vegetables contaminated by metacerceriae. The parasitosis 
commonly presents as liver disease as it is caused by hepatic flukes that deposit and 
mature into adult worms in the large biliary passages. Untreated, the disease may 
complicate into chronic granulomatous inflammation. 
The course of this parasitic disease consists of four distinct clinical phases; (i) 
incubation phase, (ii) acute or invasive phase, (iii) latent phase and (iv) chronic or 
biliary phase. Patients are commonly diagnosed in acute or chronic phases, during 
which symptoms are most apparent, prompting the patients to seek medical attention. 
Incubation phase, which ranges from several days to two or three months, refers to the 
period beginning from the ingestion of metacercariae to the manifestations of the initial 
symptoms. The acute or invasive phase occurs during the migration of juvenile flukes 
along the passages of biliary tree and liver where maturation takes place, giving rise to 
symptoms such as fever, general malaise, loss of appetite, abdominal pain, nausea and 
diarrhoea. The duration of this period ranges from two to four months. In the latent 
phase, patients are asymptomatic.  Here, the parasites mature into adult flukes in the 
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liver and begin to lay eggs, the entire process ranging from months to several years. The 
chronic phase, otherwise known as biliary or obstructive phase, occur months or years 
after infection. The symptoms that present in this phase are characteristic of hepatic 
disease due to chronic inflammation and fibrosis developed in response to long months 
of infection in the liver, potentially causing obstruction in the biliary passages. Those 
symptoms include jaundice, nausea, epigastric or right upper quadrant pain, pruritis, 
intolerance to fatty food and even cholelithiasis. (CDC, n.d.; Ashrafi et al, 2014).  
However, there are instances where the immature flukes deviate from the typical 
path along the biliary tree during their migration, entering other organs and causing 
ectopic fascioliasis. The most frequent organs affected by this deviation are those along 
the gastrointestinal tract. The lesions have also been reported to be found in lymph 
nodes, heart and blood vessels, muscles, lungs, pancreas, spleen, subcutaneous tissues, 
epididymis, brain and spine (Mas-Coma et al, 2014). Intracranial disease due to fluke 
migration into the brain is known as neurofascioliasis and is manifested by neurological, 
meningeal or psychiatric symptoms, whereas ocular symptoms indicate presence of 
infection in the orbits, otherwise known as ophthalmofascioliasis. Both instances of 




2.6 Clinical Approach to Diagnosis and Treatment 
The process of confirming diagnosis of human fascioliasis requires examination of 
clinical manifestations as well as indicative results from parasitological or serological 
investigations (Hillyer, 1999; Tran et al, 2019). Prior to 1990s, diagnosis of human 
fascioliasis had been individual-based, guided by presence of eosinophilia (increased 
eosinophil count in the blood) had been sufficient without the need to resort to stool 
analysis, as co-infections were rare in autochthonous people hence there was less risk 
of misdiagnosis. Diagnosis by serology was done through passive detection of cases 
when patients come to seek treatment during the invasive phase of infection. 
Information obtained through history-taking which pinpoints to the source of a well-
known aquatic vegetation associated with human fascioliasis, is helpful in reaching a 
diagnosis. Starting in the mid-1990s, field studies conducted demonstrate heterogenous 
transmission patterns and epidemiological scenarios that had been previously neglected, 
thus calling for the need of community surveys (Mas-coma, et al 2014).  
Stool examination to recover fasciolid eggs is only useful 3 – 4 months post 
infection (p.i.). Serology is thus usually utilized for earlier detection of infection (i.e. 
invasive or acute phase); as early as 2 weeks p.i., for anti-Fasiola abs detection, or 8 
weeks for antigen detection. Furthermore, flukes may not have achieved maturity as 
humans are “generally believed to be poor fasciolia hosts” (Mas-Coma et al, 2014), 
resulting in only small percentage of patients with eggs in their stool sample in non-
endemic regions. Analysis of infective burden by quantifying egg number per faecal 
gram (epg), however is only useful in human endemic areas with very high intensity 
infections. Despite that, epg was proven to not necessarily reflect adult fluke number in 
animal fascioliasis, it is nevertheless the only method available to indirectly assess 
infective burden, intensity-related pathogenicity and post-treatment colic risk. For 
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patients in the biliary or chronic phase who are shedding eggs, the disappearance of 
eggs is the most frequent criterion used to establish successful treatment in post-
treatment surveillance using coprological examination. For patient in the invasive 
phase, resolution of clinical symptoms, eosinophilia and hepatic function, indicate 
successful treatment. Invasive and imaging techniques such as laparoscopy and 
ultrasound are also be helpful for this scenario (Mas-Coma et al, 2014). 
Chemotherapy is the mainstay of treatment for helminthiases, and 
triclabendazole, a derivative of benzimidazole, is the drug of choice for treating 
fascioliasis. This drug was initially developed for treatment of veterinary fascioliasis in 
livestock and its use in humans began in 1990s after the reduced manufacturing of 
bithionol, the traditional medication for fascioliasis in humans (Gandhi et al, 2019). 
Triclabendazole is administered as a single post-prandial dose of 10 mg/kg, and a 
repeated dose is recommended after 12 or 24 hours for patients with severe infection 
(Keiser and Utzinger, 2009). In the event of treatment failure from this initial 
administration, a doubled dose (20 mg/kg) is recommended and should be administered 
as split doses 12 to 24 hours apart. Resistance to triclabendazole in human fascioliasis 
has been reported (Diaz et al, 2010; Cabada et al, 2016), however such cases appear to 
be rare and sporadic compared with livestock where triclabendazole use has been 
widespread and its resistance well-established. Triclabendazole still remains the 
WHO’s current recommended drug of choice for human fascioliasis (WHO, n.d.). 
2.7 Laboratory Diagnostic Approaches 
There are generally three main modalities of laboratory investigation to diagnose human 
fascioliasis, which include parasitological testing, serological or immuno-diagnosis, 
and molecular diagnosis. Although complementary testing using imaging techniques 
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such as ultrasound, computer topography (CT) scan and magnetic resonance imaging 
(MRI) have been utilized to aid in diagnosis during infections in chronic or obstructive 
phase to visualize the biliary tree (Keiser and Utzinger, 2009): 
2.7.1 Parasitological Diagnosis 
This technique involves recovery of fasciolid eggs in stool samples or samples obtained 
from gastric, duodenal or biliary lavage. Parasitological test has long been the gold 
standard to reach definitive diagnosis of human fascioliasis despite its many 
disadvantages. Fasciolid eggs are only detectable after 3 – 4 months of prepatent period 
(Chen and Mott, 1990; Valero et al, 2012b), hence stool examination is unreliable in 
early diagnosis of human fascioliasis. In chronic fascioliasis, fasciolid eggs may be 
detected in stool samples but the inherently insensitive faecal smear microscopy 
technique often escapes detection of infected individuals with light infections. 
Complete absence of eggs in a stool sample even in biliary phase of disease during 
which oviposition should occur is not uncommon due to poor quantity or irregularly 
intermittent nature of eggs shedding (Attallah et al, 2013). Humans are also recognized 
as poor hosts for Fasciola spp. and the liver flukes often do not achieve full maturation 
thus failing to produce eggs, which could lead to negative stool samples despite repeated 
examinations. Eggs may also be absent in ectopic fascioliasis.  (Mas-Coma et al, 2014; 
Sarkari and Khabisi, 2017; Tran et al, 2019).  
Sedimentation techniques, such as formalin-ether or formalin-ethyl-acetate 
techniques, are favoured over flotation techniques due to their superior accuracy and 
sensitivity (Chen and Mott, 1990; Mas-Coma et al, 1999; Mas-Coma et al, 2014a). They 
are also well established in routine diagnostic laboratories, and methods such as 
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FLOTAC (Cringoli, et al, 2010) and Flukefinder (Flukefinder Diagnostic System®, 
USA) are available. The cellophane faecal thick-smear technique, or Kato-Katz, is also 
commonly used  in both qualitative analysis and egg quantification due to its simplicity, 
rapidity, low cost and reproducibility – advantages that allow this method to be 
applicable under field conditions (Keiser and Utzinger, 2009; Mas-Coma et al, 2014a).  
2.7.2 Immunodiagnosis 
Immunodiagnostic tests are currently the best method for diagnosis of Fasciola spp. 
infection. These tests based on detection of specific antibodies or antigens in an infected 
person. It is a favoured approach that overcomes the issue of low sensitivity associated 
with parasitological diagnosis, particularly in the invasive phase of infection or in 
situations where egg production is poor due to low infective burden. Anti-Fasciola 
antibodies are detectable as early as 2 weeks post-infection, allowing for much earlier 
diagnosis, faster initiation of appropriate treatment and ultimately preventing serious 
complications like cirrhosis (Mas-Coma et al, 2014). Antigens are also detectable in 
serological or stool samples at an earlier period than fasciolid eggs (i.e. at 8 weeks post-
infection). 
There are numerous immunological tests employed in the past, most of which 
are no longer used, including complement fixation, indirect haemagglutination, 
immunofluorescence assay, precipitation tests, skin tests, and radioisotope tests. 
Nowadays, the most frequently used tests in immunodiagnosis are based on indirect 
enzyme-linked immunosorbent assay or ELISA due to its ease of performance (Chen 
and Mott, 1990; Keiser and Utzinger, 2009; Mas-Coma et al, 2014). However, antibody 
detection tests do not distinguish active infection from past or resolving one. Antibodies 
